Siyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, announced its unaudited financial results for the three months ended June 30, 2022. The announcement reported  Q2 2022 revenue of $970k up 172% year-over-year, and adjusted EBITDA and Net Losses lower year-over-year; Major North American carrier and international distributor agreements signed in Q2 2022 and subsequent to quarter end are driving accelerated sales growth of new rugged SD7 push-to-talk device and accessories; and the company will host a conference call for shareholders on Friday, August 19, at 8:00 a.m. ET.

Odyssey Health, Inc. (OTC: ODYY), a company focused on developing unique, life-enhancing medical products, announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was safe and well tolerated. The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and falls in elderly assistive-living facilities.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2022, and recent business progress.

“We continued to advance our therapeutic programs during the second quarter,” said Michael Dudley, co-founder, president and CEO of TransCode. “We remain on track to submit an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial with TTX-MC138 in cancer patients with advanced solid tumors. In addition, we were granted orphan drug designation by the US Food and Drug Administration (FDA) for TTX-siPDL1 for pancreatic cancer, and we continued preclinical studies with our other therapeutic candidates in a variety of tumor indications. In May, we were awarded the second tranche of additional non-dilutive funding from our NIH grant. We believe that these funds, along with our existing cash, provide sufficient runway to carry us into the first quarter of 2023.”

TEL AVIV, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that it has signed a non-binding letter of intent (“LOI”) with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire from it its rights to purchase, a top-seller Amazon.com account and American food supplements and cosmetics brand and trademark. The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories.